Nixon DR, et al. - In this trial, authors examined the differences in the following parameters: Sensitivity (CS), visual acuity (VA), central retinal thickness (CRT), and vision-related quality of life among patients with recalcitrant diabetic macular edema switched from long-term ranibizumab treatment to aflibercept. It was noted that the shift from ranibizumab to aflibercept in individuals with recalcitrant diabetic macular edema caused an improvement in all measured metrics, including CS, VA, and CRT. An improvement in the vision-related quality of life was found in maximum patients. A stronger correlation was determined between changes in CRT and CS compared with changes in CRT and BCVA, which pointed out that the inclusion of CS as an endpoint could impart a complete comprehension of the visual outcomes than that obtained via VA alone.